C 525

Also Known As:

2,3,5,6-(1H,4H)-tetrahydro-9-(2'-benzimidazolyl)quinolizin(9,9a,1-gh)coumarin; C-525

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Guillain-Barre Syndrome 02/01/1995 - "Four isolates from paralysis cases classified as Guillain Barré Syndrome (GBS; three with sequels) were analyzed; one presented G-->A (480) and C-->U (6203) mutations, one G-->A (480) mutation, one G-->A (480) and U-->C (525) mutations, and one did not mutate at the analyzed positions. "
2.	Gingival Overgrowth 03/01/2000 - "Among the test groups, the most remarkable gingival overgrowth was seen in group E (1,020 +/- 63.3 microm), followed by group F (895 +/- 43.8 microm), group B (870 +/- 48.3 microm), group C (525 +/- 116 microm), and then group D (505 +/- 83.2 microm). "
3.	Paralysis (Palsy) 02/01/1995 - "Four isolates from paralysis cases classified as Guillain Barré Syndrome (GBS; three with sequels) were analyzed; one presented G-->A (480) and C-->U (6203) mutations, one G-->A (480) mutation, one G-->A (480) and U-->C (525) mutations, and one did not mutate at the analyzed positions. "
4.	Facial Paralysis (Facial Palsy) 02/01/1995 - "Two isolates from transient facial paralysis cases were analyzed; one presented U-->C (525) mutation and the other G-->A (480) mutation. "